CMLTU - EQRx Goes Public

• Early last year, I wrote about a startup called EQRx, whose stated mission is to provide lower-cost alternatives to existing drugs.
• In this case, the SPAC is CM Life Sciences III (CMLTU), trading on the NASDAQ under the symbol CMLTU, that will fuse with EQRx in a deal that is expected to provide the company with up to 1.8 billion in capital.
• I notice that the company’s original talk of screening and discovering new molecules seems to have faded out a bit – they now seem to be in the mood to acquire fast-follower compounds from other people, particularly companies in China.

For further details see: